Bangma C H, Verhagen P C
Department of Urology, Erasmus University and Academic Hospital, 3015 GD Rotterdam, The Netherlands.
Microsc Res Tech. 2000 Dec 1;51(5):430-5. doi: 10.1002/1097-0029(20001201)51:5<430::AID-JEMT5>3.0.CO;2-1.
Serummarkers for prostate carcinoma are widely applied for the purpose of early detection of cancer and the differentiation between benign and malignant disease, for the pre-treatment staging of detected prostatic cancers, and for the monitoring of prostate cancer after curative or palliative therapies. This review illustrates the limitations of current markers for prostatic disease in blood en serum. It gives an overview of what is known about PSA and its isoforms, hK2, PSMA, and PSCA, and discusses, based on this information, in what direction current research is developing in order to improve these markers.
前列腺癌的血清标志物被广泛应用于癌症的早期检测、良性与恶性疾病的鉴别、已检测到的前列腺癌的治疗前分期以及根治性或姑息性治疗后前列腺癌的监测。本综述阐述了目前血液和血清中前列腺疾病标志物的局限性。它概述了关于前列腺特异性抗原（PSA）及其异构体、人激肽释放酶2（hK2）、前列腺特异性膜抗原（PSMA）和前列腺干细胞抗原（PSCA）的已知信息，并基于这些信息讨论了当前研究为改进这些标志物正朝着什么方向发展。
